Nkarta (NKTX) Competitors $2.28 -0.21 (-8.23%) As of 11:28 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NKTX vs. CMPS, NAGE, SIGA, CMPX, OPT, SVRA, KALV, BCYC, CTMX, and RGNXShould you be buying Nkarta stock or one of its competitors? The main competitors of Nkarta include COMPASS Pathways (CMPS), Niagen Bioscience (NAGE), Siga Technologies (SIGA), Compass Therapeutics (CMPX), Opthea (OPT), Savara (SVRA), KalVista Pharmaceuticals (KALV), Bicycle Therapeutics (BCYC), CytomX Therapeutics (CTMX), and REGENXBIO (RGNX). These companies are all part of the "pharmaceutical products" industry. Nkarta vs. Its Competitors COMPASS Pathways Niagen Bioscience Siga Technologies Compass Therapeutics Opthea Savara KalVista Pharmaceuticals Bicycle Therapeutics CytomX Therapeutics REGENXBIO Nkarta (NASDAQ:NKTX) and COMPASS Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk. Do insiders and institutionals have more ownership in NKTX or CMPS? 80.5% of Nkarta shares are owned by institutional investors. Comparatively, 46.2% of COMPASS Pathways shares are owned by institutional investors. 8.4% of Nkarta shares are owned by insiders. Comparatively, 3.9% of COMPASS Pathways shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has better earnings & valuation, NKTX or CMPS? COMPASS Pathways is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNkartaN/AN/A-$108.79M-$1.48-1.54COMPASS PathwaysN/AN/A-$155.12M-$1.84-3.42 Do analysts rate NKTX or CMPS? Nkarta presently has a consensus target price of $13.50, suggesting a potential upside of 490.81%. COMPASS Pathways has a consensus target price of $16.00, suggesting a potential upside of 154.57%. Given Nkarta's higher possible upside, analysts plainly believe Nkarta is more favorable than COMPASS Pathways.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nkarta 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50COMPASS Pathways 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67 Is NKTX or CMPS more profitable? Nkarta's return on equity of -27.74% beat COMPASS Pathways' return on equity.Company Net Margins Return on Equity Return on Assets NkartaN/A -27.74% -22.38% COMPASS Pathways N/A -87.89%-57.77% Does the media prefer NKTX or CMPS? In the previous week, COMPASS Pathways had 8 more articles in the media than Nkarta. MarketBeat recorded 10 mentions for COMPASS Pathways and 2 mentions for Nkarta. Nkarta's average media sentiment score of 0.77 beat COMPASS Pathways' score of 0.64 indicating that Nkarta is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nkarta 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive COMPASS Pathways 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, NKTX or CMPS? Nkarta has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, COMPASS Pathways has a beta of 2.21, meaning that its share price is 121% more volatile than the S&P 500. SummaryNkarta beats COMPASS Pathways on 9 of the 13 factors compared between the two stocks. Get Nkarta News Delivered to You Automatically Sign up to receive the latest news and ratings for NKTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NKTX vs. The Competition Export to ExcelMetricNkartaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$163.01M$3.40B$6.08B$10.48BDividend YieldN/A2.29%5.73%4.78%P/E Ratio-1.5522.6784.6926.97Price / SalesN/A477.88596.04130.44Price / CashN/A46.9737.8662.13Price / Book0.4010.3912.286.56Net Income-$108.79M-$52.47M$3.32B$276.78M7 Day Performance5.79%1.53%1.30%0.80%1 Month Performance19.63%13.74%8.49%4.02%1 Year Performance-42.88%12.10%72.74%34.82% Nkarta Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NKTXNkarta2.4406 of 5 stars$2.29-8.2%$13.50+490.8%-42.6%$163.01MN/A-1.55140Gap DownCMPSCOMPASS Pathways2.9701 of 5 stars$6.29+1.1%$16.00+154.4%+2.1%$596.76MN/A-3.42120News CoverageGap DownNAGENiagen Bioscience2.6472 of 5 stars$7.46-0.3%$13.42+79.9%N/A$596.55M$99.60M35.53120SIGASiga Technologies1.9368 of 5 stars$8.26+0.5%N/A+22.8%$588.60M$138.72M7.3140Options VolumeCMPXCompass Therapeutics2.8092 of 5 stars$4.28+0.9%$13.10+206.1%+128.3%$586.32M$850K-9.5120OPTOpthea0.3654 of 5 stars$3.41+7.2%$1.33-60.9%-32.9%$583.10M$30K0.008News CoverageAnalyst ForecastGap UpHigh Trading VolumeSVRASavara3.0807 of 5 stars$3.41+1.2%$7.50+119.9%-4.3%$582.46MN/A-6.8220Trending NewsAnalyst UpgradeAnalyst RevisionKALVKalVista Pharmaceuticals3.6643 of 5 stars$11.32-1.6%$26.43+133.5%-10.5%$581.02MN/A-2.87100BCYCBicycle Therapeutics3.5543 of 5 stars$8.12-2.4%$22.22+173.7%-68.6%$576.63M$35.28M-2.31240News CoverageAnalyst ForecastCTMXCytomX Therapeutics4.3323 of 5 stars$3.40+1.2%$5.42+59.3%+178.0%$554.11M$138.10M6.07170RGNXREGENXBIO4.4232 of 5 stars$11.34+3.8%$28.38+150.2%+14.8%$551.61M$83.33M-3.30370Gap Down Related Companies and Tools Related Companies COMPASS Pathways Competitors Niagen Bioscience Competitors Siga Technologies Competitors Compass Therapeutics Competitors Opthea Competitors Savara Competitors KalVista Pharmaceuticals Competitors Bicycle Therapeutics Competitors CytomX Therapeutics Competitors REGENXBIO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NKTX) was last updated on 10/17/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nkarta, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nkarta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
